Publication: Acetylation and deacetylation in cancer stem-like cells
Open/View Files
Date
2017
Authors
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Impact Journals LLC
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Liu, Na, Shiqi Li, Nan Wu, and Kin-Sang Cho. 2017. “Acetylation and deacetylation in cancer stem-like cells.” Oncotarget 8 (51): 89315-89325. doi:10.18632/oncotarget.19167. http://dx.doi.org/10.18632/oncotarget.19167.
Research Data
Abstract
Cancer stem-like cell (CSC) model has been established to investigate the underlying mechanisms of tumor initiation and progression. The imbalance between acetylation and deacetylation of histone or non-histone proteins, one of the important epigenetic modification processes, is closely associated with a wide variety of diseases including cancer. Acetylation and deacetylation are involved in various stemness-related signal pathways and drive the regulation of self-renewal and differentiation in normal developmental processes. Therefore, it is critical to explore their role in the maintenance of cancer stem-like cell traits. Here, we will review the extensive dysregulations of acetylation found in cancers and summarize their functional roles in sustaining CSC-like properties. Additionally, the use of deacetyltransferase inhibitors as an effective therapeutic strategy against CSCs is also discussed.
Description
Other Available Sources
Keywords
cancer stem cell, acetylation, deacetylation, HDAC, HAT
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service